Epidermal Necrolysis clinical trials

Explore recruiting epidermal necrolysis clinical trials.

Recruiting epidermal necrolysis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Epidermal Necrolysis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

New therapeutic approach to Toxic Epidermal Necrolysis (TEN) using anti-CD38+ antibodies in the active phase of the disease – Phase I/II study to assess the tolerance and efficacy of DARATUMUMAB - NET-CD38 Study

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Empirical Meropenem versus Piperacillin/Tazobactam for Adult Patients with Sepsis (EMPRESS) trial

Denmark, Sweden

Therapeutic use (Phase IV) EU CTIS Study details

Epidermal Necrolysis trials by city

Epidermal Necrolysis in Toronto Epidermal Necrolysis in Vancouver Epidermal Necrolysis in Montreal Epidermal Necrolysis in Calgary Epidermal Necrolysis in Edmonton Epidermal Necrolysis in Ottawa Epidermal Necrolysis in Winnipeg Epidermal Necrolysis in Quebec City Epidermal Necrolysis in Hamilton Epidermal Necrolysis in Kitchener Epidermal Necrolysis in London Epidermal Necrolysis in Halifax Epidermal Necrolysis in New York Epidermal Necrolysis in Los Angeles Epidermal Necrolysis in Chicago Epidermal Necrolysis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease